A new radiopharmaceutical has emerged, showing potential for use in scenarios following Pluvicto treatment. This development could signify a shift in therapeutic options available to patients.
In addition to this promising radiopharmaceutical, recent updates include data from Abivax regarding ulcerative colitis and the discontinuation of a sickle cell drug by Fulcrum.
These advancements reflect ongoing innovation in the biotech sector, with companies exploring various avenues to address unmet medical needs.